<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perflutren protein type A: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perflutren protein type A: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Perflutren protein type A: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12042" href="/d/html/12042.html" rel="external">see "Perflutren protein type A: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709205"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiopulmonary reactions: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3033664"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Optison</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3033667"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F3034064"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bcffb23a-c490-4d7a-80ca-f1cf44482457">Opacification of left ventricle</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opacification of left ventricle:</b>
<b>IV:</b> 0.5 mL via peripheral vein; flush with D<sub>5</sub>W or NS following dose; may repeat in increments of 0.5 mL up to 5 mL cumulatively in 10 minutes (maximum total dose: 8.7 mL in any one patient study).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990352"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987724"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F3034065"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F3033677"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1%), flushing (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (2%), nausea (≤4%), vomiting (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (≤1%), dizziness (3%), fatigue (≤1%), headache (5%), malaise (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%), flu-like symptoms (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin discoloration at injection site, skin rash, skin sclerosis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Oxygen desaturation (due to coughing)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Body pain, irritability, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, burning sensation of eyes, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, bradycardia, edema, hypertension, hypotension, peripheral edema, shock, supraventricular cardiac arrhythmia, supraventricular tachycardia, syncope, tachycardia, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Palatal edema</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, mouth edema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Facial hypoesthesia, loss of consciousness, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, hypoxia, pharyngeal edema, respiratory distress, stridor</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Swelling (facial swelling, swelling of eye, swelling of lips, swollen tongue, upper airway swelling)</p></div>
<div class="block coi drugH1Div" id="F3033673"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to perflutren, albumin, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F3033674"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious anaphylactoid reactions (eg, shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema [oropharyngeal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema) have been reported in patients with no prior exposure. Monitor for signs and symptoms of anaphylactoid reactions. Equipment for resuscitation and trained personnel should be readily available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious cardiopulmonary reactions: Risk may be increased in patients with unstable cardiopulmonary conditions (eg, acute MI, acute coronary artery syndromes, worsening or unstable heart failure, serious ventricular arrhythmias). However, multiple retrospective and prospective studies involving the use of perflutren-based ultrasound contrast agents have suggested they may be safely used in patients with significant cardiopulmonary disease (ie, acute coronary syndromes, heart failure, COPD, pulmonary hypertension) or critical illness (Dolan 2009; Kurt 2009; Kusnetzky 2008; Main 2008; Main 2014; Nucifora 2008; Wei 2008; Wei 2012; Weiss 2012; Wever-Pinzon 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ventricular arrhythmias: High ultrasound mechanical indices with or without end-systolic triggering may cause ventricular arrhythmias. Use is not recommended at mechanical indices &gt;0.8.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac shunts: Assess patients for embolic phenomena following administration; microspheres can bypass filtering of the lung and enter the arterial circulation in patients with a cardiac shunt. Patients with small degrees of right-to-left shunting through patent foramen ovales (those that result in transient appearance of saline contrast in the left atrium or ventricle and do not fill the left atrial or LV cavity) are not considered at an increased risk for microvascular occlusion with perflutren-based ultrasound contrast agents (ASE [Porter 2014]; Kalra 2014; Muskula 2017; Parker 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Product contains albumin; may carry a remote risk of virus transmission or hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For IV administration; do not administer by intra-arterial injection.</p></div>
<div class="block foc drugH1Div" id="F3034070"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Optison: Perflutren 0.11-0.33 mg and protein-type A microspheres 5-8 x 10<sup>8</sup> per mL (3 mL) [contains human albumin 10 mg/mL]</p></div>
<div class="block geq drugH1Div" id="F3033665"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F3034066"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV use only; do not administer intra-arterially. While allowing the vial to come to room temperature, invert and gently rotate to resuspend the microspheres; solution should appear opaque and milky-white. Do <b>not</b> use if solution is clear. Vent vial with a sterile vent spike or 18-gauge needle. Do <b>not </b>inject air into vial. Within 1 minute of resuspension, remove dose from the vial and inject using a ≥20-gauge angiocatheter into a peripheral vein at a rate ≤1 mL/second. Flush line with D<sub>5</sub>W or NS immediately after injection. Repeat resuspension prior to injection if more than 1 minute elapses.</p></div>
<div class="block use drugH1Div" id="F3033668"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Opacification of left ventricle:</b> Opacification of left ventricle and improvement of delineation of the left ventricular endocardial borders in patients with suboptimal echocardiograms</p></div>
<div class="block cyt drugH1Div" id="F13299853"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222246"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F3033670"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20617653"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if perflutren protein type A is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother</p></div>
<div class="block mop drugH1Div" id="F3034069"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiopulmonary reactions (rare); signs and symptoms of anaphylactoid reactions (rare). Monitor patient as appropriate based upon patient clinical disposition; specific monitoring parameters based upon perflutren lipid microspheres administration are not necessary (Muskula 2017).</p></div>
<div class="block pha drugH1Div" id="F3033996"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Perflutren is a stable gas that provides an echogenic contrast effect in the blood and allows for improved delineation of the left ventricular endocardial border.</p></div>
<div class="block phk drugH1Div" id="F3033998"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Contrast enhancement: Dose dependent: 1 minute (0.2 mL) to 5 minutes (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Perflutren: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.3 ± 0.69 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Perflutren: Lungs</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27000891"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Optison</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Optison</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19118722">
<a name="19118722"></a>Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. <i>J Am Coll Cardiol.</i> 2009;53(1):32-38. doi: 10.1016/j.jacc.2008.08.066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/19118722/pubmed" id="19118722" target="_blank">19118722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24524748">
<a name="24524748"></a>Kalra A, Shroff GR, Erlien D, et al. Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts. <i>JACC Cardiovasc Imaging.</i> 2014;7(2):206-207. doi: 10.1016/j.jcmg.2013.11.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/24524748/pubmed" id="24524748" target="_blank">24524748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19245974">
<a name="19245974"></a>Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. <i>J Am Coll Cardiol.</i> 2009;53(9):802-810. doi: 10.1016/j.jacc.2009.01.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/19245974/pubmed" id="19245974" target="_blank">19245974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18436124">
<a name="18436124"></a>Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. <i>J Am Coll Cardiol.</i> 2008;51(17):1704-1706. doi: 10.1016/j.jacc.2008.03.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/18436124/pubmed" id="18436124" target="_blank">18436124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19064035">
<a name="19064035"></a>Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). <i>Am J Cardiol.</i> 2008;102(12):1742-1746. doi: 10.1016/j.amjcard.2008.08.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/19064035/pubmed" id="19064035" target="_blank">19064035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290568">
<a name="24290568"></a>Main ML, Hibberd MG, Ryan A, et al. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. <i>JACC Cardiovasc Imaging.</i> 2014;7(1):40-48. doi: 10.1016/j.jcmg.2013.08.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/24290568/pubmed" id="24290568" target="_blank">24290568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377467">
<a name="28377467"></a>Muskula PR, Main ML. Safety with echocardiographic contrast agents. <i>Circ Cardiovascular Imaging.</i> 2017;10(4). pii: e005459. doi: 10.1161/CIRCIMAGING.116.005459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/28377467/pubmed" id="28377467" target="_blank">28377467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18635517">
<a name="18635517"></a>Nucifora G, Marsan NA, Siebelink HM, et al. Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction. <i>Eur J Echocardiogr.</i> 2008;9(6):816-818. doi: 10.1093/ejechocard/jen167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/18635517/pubmed" id="18635517" target="_blank">18635517</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Optison (perflutren protein type A microspheres) [prescribing information]. Marlborough, MA: GE Healthcare Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23816393">
<a name="23816393"></a>Parker JM, Weller MW, Feinstein LM, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.<i> Am J Cardiol.</i> 2013;112(7):1039-1045. doi: 10.1016/j.amjcard.2013.05.042.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/23816393/pubmed" id="23816393" target="_blank">23816393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085408">
<a name="25085408"></a>Porter TR, Abdelmoneim S, Belcik JT, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography.<i> J Am Soc Echocardiogr.</i> 2014;27(8):797-810. doi: 10.1016/j.echo.2014.05.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/25085408/pubmed" id="25085408" target="_blank">25085408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18848430">
<a name="18848430"></a>Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. <i>J Am Soc Echocardiogr.</i> 2008;21(11):1202-1206. doi: 10.1016/j.echo.2008.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/18848430/pubmed" id="18848430" target="_blank">18848430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22365709">
<a name="22365709"></a>Wei K, Main ML, Lang RM, et al. The effect of Definity on systemic and pulmonary hemodynamics in patients. <i>J Am Soc Echocardiogr.</i> 2012;25(5):584-588. doi: 10.1016/j.echo.2012.01.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/22365709/pubmed" id="22365709" target="_blank">22365709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22560734">
<a name="22560734"></a>Weiss RJ, Ahmad M, Villanueva F, et al. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice. <i>J Am Soc Echocardiogr.</i> 2012;25(7):790-795. doi: 10.1016/j.echo.2012.04.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/22560734/pubmed" id="22560734" target="_blank">22560734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22427401">
<a name="22427401"></a>Wever-Pinzon O, Suma V, Ahuja A, et al. Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study. <i>Eur Heart J Cardiovasc Imaging.</i> 2012;13(10):857-862. doi: 10.1093/ehjci/jes057.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-protein-type-a-drug-information/abstract-text/22427401/pubmed" id="22427401" target="_blank">22427401</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10335 Version 86.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
